- Bioavailability measures the amount of a substance that enters the bloodstream, with most oral routes providing lower amounts of the drug due to poor bioavailability
- Studies on nutrients show that not all the nutrients we ingest actually enter the bloodstream due to inhibiting factors in the digestive tract
- Lexaria’s patented DehydraTECH(TM) technology helps increase bioavailability for active pharmaceutical ingredients (“APIs”), which has been shown through various animal and human clinical studies
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, is using its patented DehydraTECH(TM) technology to improve bioavailability and how active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery, helping with the speed of onset, and brain absorption. Lexaria is focusing ongoing research and development efforts on the advancement of product candidates across several key segments, including, nicotine replacement, CBD, cardiovascular drugs, antivirals, epilepsy, human hormones, and PDE5 inhibitors.
Bioavailability measures how much of a substance enters the bloodstream, with intravenous administration being the most effective approach to 100% bioavailability for maximum effect. While oral administration is less intrusive and preferred, it presents less efficacy and bioavailability of APIs due to obstacles like gut disorders and stomach acid and liver biotransformation.
Although Lexaria is focused on pharmaceutical bioavailability, it’s interesting to note that bioavailability even plays a role in nutrition. While macronutrients (carbs and fat) offer higher levels of bioavailability – micronutrients, commonly sold as supplements (vitamins, minerals, flavonoids, and carotenoids), can be harder for the body to absorb. Studies show that not all the nutrients we eat enter the bloodstream after entering the digestive tract. Some factors that affect bioavailability include where the food is grown or made, when it was harvested, how it was prepared, the foods you eat with it, and highly individualized physiological traits that affect how your body processes that food.
With studies showing that around 40% of available drugs are poorly bioavailable (https://ibn.fm/xy86j), the determined factors that affect drug bioavailability include:
- The size of the drug’s molecule
- The type of drug administered
- The amount of food eaten
- The time of day the drug is taken
Understanding the bioavailability of a drug is crucial for clinicians looking for appropriate routes of administration and schedule for drug delivery. Lexaria is investigating its DehydraTECH technology for increased bioavailability of APIs with epilepsy, high blood pressure, dementia, diabetes, and more.
The global pharmaceutical drug delivery market is projected to reach $2.21 billion by 2026, growing with a CAGR of 5.9% from a value of $1.66 billion in 2021. Growth is highly attributed to factors including the rising prevalence of chronic diseases, the growing biologics market, increased R&D investments, and technological advancements, which include new product launches (https://ibn.fm/cJq4l).
Animal studies have also demonstrated a propensity for DehydraTECH technology to elevate the quantity of drug delivered across the blood-brain barrier by as much as 1,900 percent, initiating additional new patent applications and opening possibilities for improved drug delivery. Since 2016, Lexaria’s technology has repeatedly demonstrated, with cannabinoids and nicotine, the ability to increase bio-absorption by up to five to ten times, reduce the onset time from one to two hours to just minutes, and mask unwanted tastes.
The company’s recent study, EPIL-A21-1, demonstrated performance enhancements compared to one of the world’s leading anti-seizure medications, Epidiolex(R). The study’s results have demonstrated the performance of DehydraTECH-CBD to reduce or eliminate seizure activity in animals and, in some cases, even surpass the performance of Epidiolex. The findings from the study further support Lexaria’s efforts and clinical trials, which are currently being explored for other indications, including hypertension, dementia, and diabetes. The indications explored by Lexaria are chosen due to their current underserved medical needs, as DehydraTECH helps enhance bioavailability of substances for treatment.
For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX
TinyGems is your guide to the best and brightest in the under-appreciated small-cap sector. As one of 50+ brands within the InvestorBrandNetwork (“IBN”), TinyGems provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) social media distribution via IBN to reach millions of social media followers; and (5) a full array of corporate communications solutions. It’s time to uncover some of the best-kept secrets on Wall Street. TinyGems features innovative small-cap companies with huge potential, putting a spotlight on the best and brightest of these disruptors that have the technology, the talent, the drive, and the business models to make a huge impact in the markets and in portfolios. Whether it’s a game changing technology, a new more profitable product or service, or a star in a hot sector, TinyGems is the go-to source for actionable intelligence.
To receive SMS text alerts from TinyGems, text “Gems” to 844-397-5787 (U.S. Mobile Phones Only)
For more information, please visit https://www.TinyGems.com
TinyGems is part of the InvestorBrandNetwork